Updates on Clinical Use of Liquid Biopsy in Colorectal Cancer Screening, Diagnosis, Follow-Up, and Treatment Guidance

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Jun 21

PMID 34150757

Citations 29

Authors

Omayma Mazouji

Abdelhak Ouhajjou

Roberto Incitti

Hicham Mansour

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is one of the most common cancers worldwide, being the third most diagnosed in the world and the second deadliest. Solid biopsy provides an essential guide for the clinical management of patients with colorectal cancer; however, this method presents several limitations, in particular invasiveness, and cannot be used repeatedly. Recently, clinical research directed toward the use of liquid biopsy, as an alternative tool to solid biopsy, showed significant promise in several CRC clinical applications, as (1) detect CRC patients at early stage, (2) make treatment decision, (3) monitor treatment response, (4) predict relapses and metastases, (5) unravel tumor heterogeneity, and (6) detect minimal residual disease. The purpose of this short review is to describe the concept, the characteristics, the genetic components, and the technologies used in liquid biopsy in the context of the management of colorectal cancer, and finally we reviewed gene alterations, recently described in the literature, as promising potential biomarkers that may be specifically used in liquid biopsy tests.

Citing Articles

Development and validation of a radiopathomics model for predicting liver metastases of colorectal cancer.

Jing H, Hao D, Liu X, Cui M, Xue K, Wang D Eur Radiol. 2024; .

PMID: 39621056 DOI: 10.1007/s00330-024-11198-1.

Raman spectroscopy on dried blood plasma allows diagnosis and monitoring of colorectal cancer.

Morasso C, Daveri E, Bonizzi A, Truffi M, Colombo F, Danelli P MedComm (2020). 2024; 5(11):e774.

PMID: 39492836 PMC: 11527808. DOI: 10.1002/mco2.774.

Recent Technologies towards Diagnostic and Therapeutic Applications of Circulating Nucleic Acids in Colorectal Cancers.

Chung J, Xiao S, Gao Y, Soung Y Int J Mol Sci. 2024; 25(16).

PMID: 39201393 PMC: 11354501. DOI: 10.3390/ijms25168703.

Liquid Biopsy in the Clinical Management of Cancers.

Ho H, Chung K, Kan C, Wong S Int J Mol Sci. 2024; 25(16).

PMID: 39201281 PMC: 11354853. DOI: 10.3390/ijms25168594.

Is the development of liquid biopsy for the early detection and the monitoring of breast cancers on its way of overtaking mammography?.

Mansour H, Nejjari C, Incitti R, Anouar N, Ouhajjou A Front Med (Lausanne). 2024; 11:1415940.

PMID: 39185467 PMC: 11341495. DOI: 10.3389/fmed.2024.1415940.

References

Trojan J, Klein-Scory S, Koch C, Schmiegel W, Baraniskin A . Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer. Case Rep Oncol Med. 2017; 2017:6139634. PMC: 5292363. DOI: 10.1155/2017/6139634. View

Roperch J, Incitti R, Forbin S, Bard F, Mansour H, Mesli F . Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 2013; 13:566. PMC: 4219483. DOI: 10.1186/1471-2407-13-566. View

Bhardwaj M, Weigl K, Tikk K, Benner A, Schrotz-King P, Brenner H . Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer. Mol Oncol. 2019; 14(1):8-21. PMC: 6944100. DOI: 10.1002/1878-0261.12591. View

Wang J, Koo K, Wang Y, Trau M . Engineering State-of-the-Art Plasmonic Nanomaterials for SERS-Based Clinical Liquid Biopsy Applications. Adv Sci (Weinh). 2019; 6(23):1900730. PMC: 6891916. DOI: 10.1002/advs.201900730. View

Fernandez-Lazaro D, Hernandez J, Garcia A, Cordova Martinez A, Mielgo-Ayuso J, Cruz-Hernandez J . Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer's Biomarkers. Diagnostics (Basel). 2020; 10(4). PMC: 7235853. DOI: 10.3390/diagnostics10040215. View

Cheung A, Chow C, To K . Latest development of liquid biopsy. J Thorac Dis. 2018; 10(Suppl 14):S1645-S1651. PMC: 6035915. DOI: 10.21037/jtd.2018.04.68. View

Draht M, Goudkade D, Koch A, Grabsch H, Weijenberg M, van Engeland M . Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review. Clin Epigenetics. 2018; 10:35. PMC: 5851322. DOI: 10.1186/s13148-018-0461-8. View

Dang H, Krasnick B, White B, Grossman J, Strand M, Zhang J . The clonal evolution of metastatic colorectal cancer. Sci Adv. 2020; 6(24):eaay9691. PMC: 7286679. DOI: 10.1126/sciadv.aay9691. View

Drula R, Ott L, Berindan-Neagoe I, Pantel K, Calin G . MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods. Cancers (Basel). 2020; 12(8). PMC: 7465219. DOI: 10.3390/cancers12082009. View

10.

Arai H, Battaglin F, Wang J, Lo J, Soni S, Zhang W . Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev. 2019; 81:101912. PMC: 7491975. DOI: 10.1016/j.ctrv.2019.101912. View

11.

Wu J, Hu S, Zhang L, Xin J, Sun C, Wang L . Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis. Theranostics. 2020; 10(10):4544-4556. PMC: 7150480. DOI: 10.7150/thno.40532. View

12.

Toiyama Y, Okugawa Y, Fleshman J, Boland C, Goel A . MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review. Biochim Biophys Acta Rev Cancer. 2018; 1870(2):274-282. PMC: 7286572. DOI: 10.1016/j.bbcan.2018.05.006. View

13.

Bronte G, Silvestris N, Castiglia M, Galvano A, Passiglia F, Sortino G . New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. Oncotarget. 2015; 6(28):24780-96. PMC: 4694794. DOI: 10.18632/oncotarget.4959. View

14.

Worm Orntoft M . Review of Blood-Based Colorectal Cancer Screening: How Far Are Circulating Cell-Free DNA Methylation Markers From Clinical Implementation?. Clin Colorectal Cancer. 2018; 17(2):e415-e433. DOI: 10.1016/j.clcc.2018.02.012. View

15.

Melotte V, Yi J, Lentjes M, Smits K, Van Neste L, Niessen H . Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood. Cancer Prev Res (Phila). 2014; 8(2):157-64. PMC: 4316751. DOI: 10.1158/1940-6207.CAPR-14-0198. View

16.

Reece M, Saluja H, Hollington P, Karapetis C, Vatandoust S, Young G . The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. Front Genet. 2019; 10:1118. PMC: 6881479. DOI: 10.3389/fgene.2019.01118. View

17.

Vacante M, Ciuni R, Basile F, Biondi A . The Liquid Biopsy in the Management of Colorectal Cancer: An Overview. Biomedicines. 2020; 8(9). PMC: 7555636. DOI: 10.3390/biomedicines8090308. View

18.

Peng J, Ou Q, Pan Z, Zhang R, Zhao Y, Deng Y . Serum CNPY2 isoform 2 represents a novel biomarker for early detection of colorectal cancer. Aging (Albany NY). 2018; 10(8):1921-1931. PMC: 6128441. DOI: 10.18632/aging.101512. View

19.

Levine A, Phipps A, Baron J, Buchanan D, Ahnen D, Cohen S . Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):68-75. PMC: 4713308. DOI: 10.1158/1055-9965.EPI-15-0935. View

20.

Zhou B, Xu K, Zheng X, Chen T, Wang J, Song Y . Application of exosomes as liquid biopsy in clinical diagnosis. Signal Transduct Target Ther. 2020; 5(1):144. PMC: 7400738. DOI: 10.1038/s41392-020-00258-9. View